Please use this identifier to cite or link to this item:
|Statistics||SHARE CORE MendeleyBASE||
|Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL|
Effectiveness and safety of dual therapy with rilpivirine and boosted darunavir in treatment-experienced patients with advanced HIV infection: a preliminary 24 week analysis (RIDAR study)
|Authors:||Pasquau-Liaño, Juan; Jesus, Samantha E. de; Arazo, Piedad; Crusells, María J.; Ríos-Villegas, María José; Lozano, Fernando; Torre, Javier de la; Galindo, María José; Carmena, Jorge; Santos, Jesús; Tornero, Carlos; Verdejo, Guillermo; Samperiz, Gloria; Palacios-Baena, Zaira Raquel; Hidalgo-Tenorio, Carmen|
|Citation:||BMC Infectious Diseases 19: 207 (2019)|
|Abstract:||[Background]: The objective was to analyze the effectiveness and safety of dual therapy with rilpivirine plus boosteddarunavir (RPV + bDRV) in real-life patients.|
[Methods]: Observational, retrospective, multi-center study in HIV+ patients who had received RPV + bDRV for 24 weeks to optimize/simplify their previous antiretroviral treatment. We determined the percentage of patients without virologic failure (2 consecutive viral loads > 50 copies/mL) at 24 weeks of treatment.
[Results]: The study included 161 patients from 15 hospitals with median age of 49 years; 29.3% had previous AIDS stage and median CD4+ lymphocyte nadir of 170 cells/uL. They had been diagnosed with HIV for a median of 17 years and had received 14 years of ART, with five previous treatment combinations, and 36.6% had a history of virological failure. The reasons for the switch were simplification/optimization (49.7%), toxicity/intolerance (17.4%), or inadequate effectiveness of previous ART (10.6%). Baseline VL of 50–1000 copies/mL was recorded in 25.5% of the patients. In the“intention-to-treat” analysis at 24 weeks, 87.6% of 161 patients continued the study treatment without virologic failure criteria. In the “on treatment” analysis (excluding patients who discontinued treatment with dual therapy for any reason other than virologic failure) the efficacy was 94.6% (141/149 patients).
[Conclusions]: Dual therapy with RPV + DRVb proved to be effective and safe in patients with advanced HIV infection, long exposure to ART, low CD4 nadir, previous virologic failure, and/or history of ineffective ART.
|Publisher version (URL):||https://doi.org/10.1186/s12879-019-3817-6|
|Appears in Collections:||(IBIS) Artículos|